TEST:

ColoNode®

"Swedish biotech company HiloProbe says it has reached a significant milestone after the results of a prospective multicenter study conducted in collaboration with Umea University and eight Swedish hospitals were published in the International Journal of Cancer. The study results show that HiloProbe’s ColoNode kit can identify more patients at risk of tumor recurrence following surgery compared to the standard method used today."

Multivariate Cox regression analysis proved ColoNode (1, 2, 3 vs 0, -1) as a highly significant risk factor with HR 4.24 [95% confidence interval, 1.42-12.69, P = .01], while pTN-stage (III vs I/II) lost its univariate significance. In conclusion, ColoNode surpassed histopathology by identifying a significantly larger number of patients with future relapse and will be a valuable tool for decisions on postoperative treatment.

"Umea University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode’s benefits and usefulness in colon cancer."

"Biocartis Group NV...announce that they entered into a collaboration that will initially focus on the commercialization of ColoNode, a CE-marked IVD gene expression signature test that can help detect nodal metastasis in colorectal cancer (CRC) patients. ColoNode will be distributed as a manual kit by Biocartis to expert laboratories in selected European countries."